Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07163793 · ClinicalTrials.gov registry record · Phase 2
Pilot Study of Reduced Venetoclax Exposure
A Phase 2 study of Acute Myeloid Leukemia in Remission, sponsored by Northwell Health.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
- 1
- Study location
NCT07163793 is a Phase 2 study of Acute Myeloid Leukemia in Remission that is actively recruiting participants, run by Northwell Health. The registered enrollment target is 41 participants, below the 65-participant average among 11 other Acute Myeloid Leukemia in Remission trials with a reported enrollment target (37% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07163793, a Phase 2 study of Acute Myeloid Leukemia in Remission, is actively recruiting participants, sponsored by Northwell Health.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
- 1
- Study location
Study Summary
Pilot Study of Reduced Venetoclax Exposure
Conditions Studied
Interventions
- DRUG Venetoclax
- DRUG Azacitidine
- DRUG Decitabine
Study Locations (1)
New York
- Zuckerberg Cancer Center - New Hyde Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2024-10-07 |
| Est. Completion | 2028-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07163793
The ClinicalTrials.gov registry entry for NCT07163793 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 65-participant average among 11 other Acute Myeloid Leukemia in Remission trials with a reported enrollment target (37% lower). The listed sponsor is Northwell Health, which has 370 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acute Myeloid Leukemia in Remission appearing as the primary indexed condition, and to 3 interventions - of which Venetoclax is the first listed.
NCT07163793 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT07163793 about?
NCT07163793 is a clinical study titled "Pilot Study of Reduced Venetoclax Exposure". Pilot Study of Reduced Venetoclax Exposure
What is the current status of trial NCT07163793?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2024-10-07. Estimated completion is 2028-10.
What conditions does trial NCT07163793 study?
This clinical trial studies the following conditions: Acute Myeloid Leukemia in Remission.
What interventions are being tested in trial NCT07163793?
The interventions under investigation include: Venetoclax (DRUG), Azacitidine (DRUG), Decitabine (DRUG).
Who is sponsoring clinical trial NCT07163793?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07163793 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myeloid Leukemia in Remission
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ruxolitinib + Allogeneic Stem Cell Transplantation in AML
ACTIVE NOT RECRUITING · Phase 2
-
AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission
ACTIVE NOT RECRUITING · Phase 2
-
Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant
ACTIVE NOT RECRUITING · Phase 2
-
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
RECRUITING · Phase 1
-
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
RECRUITING · Phase 1
-
Ziftomenib Maintenance Post Allo-HCT
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.